Table 3. ELISpot and flow cytometry activity of synthesized AMA1 epitopes with protected volunteers.
| Vol. | Status | Vol. HLA | Peptide Pool | Epitope | HLA-restr. | ELISpot sfc/m | % CD8+ T Cell IFN-γ | % CD8+ T Cell EM IFN-γ |
| v10 | Protected | B*57:01 | Ap8 | 1312 | 0.061 | 0.031 | ||
| YKSHGKGYNW | B*57:01 | 1592 | 0.051 | 0.0251 | ||||
| v18 | Protected | B*58:01 | Ap8 | 1582 | 0.641 | 0.211 | ||
| YKSHGKGYNW | B*58:01 | 1812 | 0.861 | 0.311 | ||||
| v156 | Non-protected | B*58:02 | Ap8 | 1414 | 1.11B2 | 0.253 | ||
| KSHGKGYNW | B*58:02 | 884 | 1.47B2 | 0.403 | ||||
| v194 | Partially-protected | B*58:01 | Ap8 | 474 | 0.17B2 | 0.073 | ||
| KSHGKGYNW | B*58:01 | 194 | 0.22B2 | 0.083 | ||||
| v11 | Protected | A*11:01 | Ap10 | NT | 0.371 | 0.101 | ||
| NSTCRFFVCK | A*11:01 | 2481 2311 | 0.391 | 0.141 |
DNA/Ad cells collected 22/23 days after Ad boost.
DNA/Ad cells collected 84 days after malaria challenge.
AdCA cells collected 22/23 days after AdCA immunization.
Cells collected 84 days after malaria challenge. Each synthesized AMA1 predicted epitope was tested in ELISpot and flow cytometry with the parent Ap8 or Ap10 peptide pool. NT = Not Tested. Volunteer v11 was tested twice in ELISpot with predicted epitope. The Ap8 peptide pool and corresponding KSHGKGYNW (or contained within the 10mer YKSHGKGYNW) epitope recalled similar ELISpot from v10 and v18, but weaker CD8+ T cell activities from v10 than v18 (consistent with Figures 2 and 3). Ap8 and KSHGKGYNW recalled activities from partially protected v194 (consistent with Figure S1, S2, but not Figure S3 where v156 lacked EM activity). Ap8 and KSHGKGYNW also recalled activities from non-protected v156 (consistent with Figures S1, S2 and S3). Ap10 and the corresponding epitope STCRFFVCK (contained within the 10mer NSTCRFFVCK) recalled activities from v11 (consistent with Figures 2, 3 and 4).